S
Sten Madsbad
Researcher at Copenhagen University Hospital
Publications - 576
Citations - 31918
Sten Madsbad is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 87, co-authored 532 publications receiving 28980 citations. Previous affiliations of Sten Madsbad include Aalborg University & University of Copenhagen Faculty of Science.
Papers
More filters
Journal ArticleDOI
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
TL;DR: Glucagon-like peptide 1 (GLP-1) could be a new treatment for type 2 diabetes, though further investigation of the long-term effects of this peptide hormone is needed.
Journal ArticleDOI
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
TL;DR: The measurement of intact incretin hormones revealed that total as well as intact GIP responses were minimally decreased in patients with type 2 diabetes, whereas the late intact GLP-1 response was strongly reduced, supporting the hypothesis that an impaired function of GLp-1 as a transmitter in the enteroinsular axis contributes to the inappropriate insulin secretion in type 2 diabetic patients.
Journal ArticleDOI
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Anthony H. Barnett,Stephen C. Bain,Paul Bouter,Bengt E. Karlberg,Sten Madsbad,Jak Jervell,Jukka Mustonen +6 more
TL;DR: Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes and early nephropathy, and these findings support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in people with conditions that place them at high risk for cardiovascular events.
Journal ArticleDOI
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
Mai-Britt Toft-Nielsen,Mette Brimnes Damholt,Sten Madsbad,Linda Hilsted,Thomas Edward Hughes,Birgitte K. Michelsen,Jens J. Holst +6 more
TL;DR: It is concluded that the meal-related glucagon-like peptide-1 response in type 1 diabetes is decreased, which may contribute to the decreased incretin effect in type 2 diabetes.
Journal ArticleDOI
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on β-Cell Sensitivity in Type 2 and Nondiabetic Subjects
TL;DR: GLP-1 increases insulin secretion in patients with type 2 diabetes and control subjects in a dose-dependent manner and that the beta-cell responsiveness to glucose may be increased to normal levels with a low dose of GLP- 1 infusion.